Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers




BIOtechNow show

Summary: After months of criticism, including some from BIO, the Institute for Clinical and Economic Review (ICER) released a document that tries to address many of the legitimate and persistent concerns that have been raised. We appreciate that ICER is taking such criticism more seriously, and recently opened up its methodology to more public comment.  However, after reviewing the document, it remains clear to us that ICER still doesn’t quite get why so many organizations, including Read More